Objectives To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in
RAPID-PsA (NCT01087788), an ongoing Phase 3 trial in patients with psoriatic arthritis …

Objectives To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in
RAPID-axSpA (NCT01087762), an ongoing Phase 3 trial in patients with axial …

Objectives To report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of
patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr …

Objective Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine
and sacroiliac joints and can also affect extraarticular sites, with the most common …

Background The best strategy for maintaining clinical remission in patients with axial
spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation …

Objective The aim was to assess the long-term safety and efficacy of certolizumab pegol
over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA) …

Objective The natural history of nonradiographic axial spondyloarthritis (SpA) is
incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs …

Objectives To report the effect of different imputation methodologies on the assessment of
radiographic progression in clinical trials. Methods The 216-week RAPID-psoriatic arthritis …

Objective Previous reports of the RAPID‐axSpA trial (NCT01087762) described the efficacy
and safety of certolizumab pegol (CZP) over 24 weeks in patients with axial spondyloarthritis …

Background Acute anterior uveitis (AAU) affects up to 40% of patients with axial
spondyloarthritis (axSpA). An effective treatment for patients with axSpA that reduces the risk …